Ibogaine hydrochloride for opioid-related disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 1 Jul 2019: Trial registered, NCT04003948
  2. 28 Oct 2020: Trial started, NCT04003948

The trials

NCT04003948: Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

State
Completed
Phase
Phase 2
People
20 taking part
Started
28 Oct 2020
Primary completion
26 Apr 2024
Arms
Fixed dose, Ascending dose
Results
None posted
  1. 1 Jul 2019: Trial registered
  2. 28 Oct 2020: Trial started
  3. 26 Apr 2024: Trial completed

NCT05029401: A Study of Oral Ibogaine in Opioid Withdrawal

State
Completed
Phase
Phase 1 and Phase 2
People
116 taking part
Started
1 Apr 2021
Primary completion
16 Jan 2024
Arms
Single dose IMP (DMX-1002)
Results
None posted
  1. 1 Apr 2021: Trial started
  2. 31 Aug 2021: Trial registered
  3. 16 Jan 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as DMX-1002.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.